世界の性感染症(STD)検査市場2022-2029:疾患別(クラミジア、淋病、単純ヘルペスウイルス、梅毒、ヒトパピローマウイルス(HPV)、ヒト免疫不全ウイルス(HIV)、その他)、検査場所別、地域別

【英語タイトル】Global Sexually Transmitted Diseases (STD) Testing Market Size study & Forecast, by Disease Type (Chlamydia, Gonorrhea, Herpes Simplex Virus, Syphilis, Human Papillomavirus (HPV), Human Immunodeficiency Virus (HIV), and Other Diseases) and Location of Testing (Laboratory Testing, and Point-of-care (POC) Testing) and Regional Analysis, 2022-2029

Bizwit Research & Consultingが出版した調査資料(BZW22DC041)・商品コード:BZW22DC041
・発行会社(調査会社):Bizwit Research & Consulting
・発行日:2022年11月5日
・ページ数:約200
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:アメリカ、カナダ、イギリス、ドイツ、フランス、スペイン、イタリア、中国、インド、日本、オーストラリア、韓国、ブラジル、メキシコ、中東
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用、印刷不可)USD4,950 ⇒換算¥732,600見積依頼/購入/質問フォーム
Enterprisewide(同一法人内共有可)USD6,250 ⇒換算¥925,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Bizwit Research社発行の本調査レポートによると、2021年におよそ960.6億ドルであった世界の性感染症(STD)検査市場規模が、2022年から2029年の間に5.1%以上成長すると予測されています。本レポートは、性感染症(STD)検査の世界市場を対象とし、エグゼクティブサマリー、市場定義・範囲、市場動向、産業分析、リスク分析(新型コロナウイルス感染症の影響)、疾患別(クラミジア、淋病、単純ヘルペスウイルス、梅毒、その他)分析、検査場所別(ラボ検査、ポイントオブケア(POC)検査)分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、その他地域)分析、競争分析、調査プロセスなど、多面的な分析結果をまとめたものです。なお、参入企業情報として、Abbott Laboratories 、Becton Dickinson Company、 Biomérieux, Inc.、Bio-Rad Laboratories Inc.、Danaher Corporation、Diasorin Molecular Llc、Hologic Inc.、Orasure Technologies, Inc.、Roche Holdings Ag、Thermo Fisher Scientific (Affymetrix)などが含まれております。
・エグゼクティブサマリー
・市場定義・範囲
・市場動向
・産業分析
・リスク分析(新型コロナウイルス感染症の影響)

・世界の性感染症(STD)検査市場規模:疾患別
- クラミジアの市場規模
- 淋病の市場規模
- 単純ヘルペスウイルスの市場規模
- 梅毒の市場規模
- その他疾患の市場規模

・世界の性感染症(STD)検査市場規模:検査場所別
- ラボ検査の市場規模
- ポイントオブケア(POC)検査の市場規模

・世界の性感染症(STD)検査市場規模:地域別
- 北米の性感染症(STD)検査市場規模
- ヨーロッパの性感染症(STD)検査市場規模
- アジア太平洋の性感染症(STD)検査市場規模
- 中南米の性感染症(STD)検査市場規模
- その他地域の性感染症(STD)検査市場規模

・競争分析
・調査プロセス

Global Sexually Transmitted Diseases (STD) Testing Market is valued approximately USD 96.06 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 5.1% over the forecast period 2022-2029.
Sexually Transmitted Diseases (STD) refer to infection transmitted from an infected person to an uninfected person through sextual contact. STDs are caused by bacteria, and viruses. Chlamydia, Gonorrhea, Herpes Simplex Virus, Syphilis, Human Papillomavirus (HPV), and Human Immunodeficiency Virus among others are different kind of STDs. The increasing prevalence of STDs worldwide and favorable reimbursement policies for STDs as well as strategic initiatives from leading market players are key factors accelerating the market growth.

According to the World Health Organization (WHO) estimates – in 2020, globally around 374 million new cases of STIs were reported. In addition, the most prevalent type of infection was chlamydia with 129 million cases, followed by gonorrhoea with 82 million cases, syphilis with 7.1 million cases and trichomoniasis with 156 million cases. Also, growing healthcare infrastructure in the developing regions and rising patient awareness towards STD prevalence would create lucrative growth prospectus for the market over the forecast period. However, the high cost associated with testing equipment and social stigma associated with STDs impede the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Sexually Transmitted Diseases (STD) Testing Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading region in terms of market share due to factors such as presence of leading market players as well as availability of robust healthcare infrastructure in the region. Whereas Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising prevalence of STDs as well as increasing number of favorable initiatives from government authorities in terms of awareness campaigns and reimbursement policies in the region.

Major market player included in this report are:
Abbott Laboratories
Becton Dickinson Company
Biomérieux, Inc.
Bio-Rad Laboratories Inc.
Danaher Corporation
Diasorin Molecular Llc
Hologic Inc.
Orasure Technologies, Inc.
Roche Holdings Ag
Thermo Fisher Scientific (Affymetrix)

Recent Developments in the Market:
 In June 2019, Quest Diagnostics, launched three laboratory testing packages for sexually transmitted diseases (STDs). The package would cover chlamydia, gonorrhea, and syphilis, would be available for online purchase by individuals across the United States.

 In April 2022, USA based Chiricahua Community Health Centers, Inc. (CCHCI) entered in a collaboration with The Body Agency Collective (TBAC) and Visby Medical, Inc., to enhance the diagnosis and treatment of sexually transmitted infection (STI). Under this project the community health center would utilize PCR diagnostic device, the Sexual Health Click Test to test STIs in women within 30 minutes.

Global Sexually Transmitted Diseases (STD) Testing Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Disease Type, Location of Testing, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Disease Type
Chlamydia
Gonorrhea
Herpes Simplex Virus
Syphilis
Human Papillomavirus (HPV)
Human Immunodeficiency Virus (HIV)
Other Diseases

By Location of Testing
Laboratory Testing
Point-of-care (POC) Testing)

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

❖ レポートの目次 ❖

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Sexually Transmitted Diseases (STD) Testing Market, by Region, 2019-2029 (USD Billion)
1.2.2. Sexually Transmitted Diseases (STD) Testing Market, by Disease Type, 2019-2029 (USD Billion)
1.2.3. Sexually Transmitted Diseases (STD) Testing Market, by Location of Testing, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Sexually Transmitted Diseases (STD) Testing Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Sexually Transmitted Diseases (STD) Testing Market Dynamics
3.1. Sexually Transmitted Diseases (STD) Testing Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Increasing prevalence of STDs worldwide.
3.1.1.2. Favourable reimbursement policies for STDs
3.1.1.3. Strategic initiatives from leading market players.
3.1.2. Market Challenges
3.1.2.1. High cost associated with testing equipment.
3.1.2.2. Social stigma associated with STDs
3.1.3. Market Opportunities
3.1.3.1. Growing healthcare infrastructure in the developing regions.
3.1.3.2. Rising patient awareness towards STD prevalence.
Chapter 4. Global Sexually Transmitted Diseases (STD) Testing Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Investment Adoption Model
4.5. Analyst Recommendation & Conclusion
4.6. Top investment opportunity
4.7. Top winning strategies
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Sexually Transmitted Diseases (STD) Testing Market, by Disease Type
6.1. Market Snapshot
6.2. Global Sexually Transmitted Diseases (STD) Testing Market by Disease Type, Performance – Potential Analysis
6.3. Global Sexually Transmitted Diseases (STD) Testing Market Estimates & Forecasts by Disease Type 2019-2029 (USD Billion)
6.4. Sexually Transmitted Diseases (STD) Testing Market, Sub Segment Analysis
6.4.1. Chlamydia
6.4.2. Gonorrhea
6.4.3. Herpes simplex virus
6.4.4. Syphilis
6.4.5. Human papillomavirus (HPV)
6.4.6. Other diseases (human immunodeficiency virus (HIV), chancroid, trichomoniasis, and hepatitis B)
Chapter 7. Global Sexually Transmitted Diseases (STD) Testing Market, by Location of Testing
7.1. Market Snapshot
7.2. Global Sexually Transmitted Diseases (STD) Testing Market by Location of Testing, Performance – Potential Analysis
7.3. Global Sexually Transmitted Diseases (STD) Testing Market Estimates & Forecasts by Location of Testing 2019-2029 (USD Billion)
7.4. Sexually Transmitted Diseases (STD) Testing Market, Sub Segment Analysis
7.4.1. Laboratory testing
7.4.2. Point of care (POC) testing
Chapter 8. Global Sexually Transmitted Diseases (STD) Testing Market, Regional Analysis
8.1. Sexually Transmitted Diseases (STD) Testing Market, Regional Market Snapshot
8.2. North America Sexually Transmitted Diseases (STD) Testing Market
8.2.1. U.S. Sexually Transmitted Diseases (STD) Testing Market
8.2.1.1. Disease Type breakdown estimates & forecasts, 2019-2029
8.2.1.2. Location of Testing breakdown estimates & forecasts, 2019-2029
8.2.2. Canada Sexually Transmitted Diseases (STD) Testing Market
8.3. Europe Sexually Transmitted Diseases (STD) Testing Market Snapshot
8.3.1. U.K. Sexually Transmitted Diseases (STD) Testing Market
8.3.2. Germany Sexually Transmitted Diseases (STD) Testing Market
8.3.3. France Sexually Transmitted Diseases (STD) Testing Market
8.3.4. Spain Sexually Transmitted Diseases (STD) Testing Market
8.3.5. Italy Sexually Transmitted Diseases (STD) Testing Market
8.3.6. Rest of Europe Sexually Transmitted Diseases (STD) Testing Market
8.4. Asia-Pacific Sexually Transmitted Diseases (STD) Testing Market Snapshot
8.4.1. China Sexually Transmitted Diseases (STD) Testing Market
8.4.2. India Sexually Transmitted Diseases (STD) Testing Market
8.4.3. Japan Sexually Transmitted Diseases (STD) Testing Market
8.4.4. Australia Sexually Transmitted Diseases (STD) Testing Market
8.4.5. South Korea Sexually Transmitted Diseases (STD) Testing Market
8.4.6. Rest of Asia Pacific Sexually Transmitted Diseases (STD) Testing Market
8.5. Latin America Sexually Transmitted Diseases (STD) Testing Market Snapshot
8.5.1. Brazil Sexually Transmitted Diseases (STD) Testing Market
8.5.2. Mexico Sexually Transmitted Diseases (STD) Testing Market
8.6. Rest of The World Sexually Transmitted Diseases (STD) Testing Market

Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. Abbott Laboratories
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2. Becton Dickinson Company
9.2.3. Biomérieux, Inc.
9.2.4. Bio-Rad Laboratories Inc.
9.2.5. Danaher Corporation
9.2.6. Diasorin Molecular LLC
9.2.7. Hologic Inc.
9.2.8. Orasure Technologies, Inc.
9.2.9. Roche Holdings Ag
9.2.10. Thermo Fisher Scientific (Affymetrix)
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption



★調査レポート[世界の性感染症(STD)検査市場2022-2029:疾患別(クラミジア、淋病、単純ヘルペスウイルス、梅毒、ヒトパピローマウイルス(HPV)、ヒト免疫不全ウイルス(HIV)、その他)、検査場所別、地域別] (コード:BZW22DC041)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の性感染症(STD)検査市場2022-2029:疾患別(クラミジア、淋病、単純ヘルペスウイルス、梅毒、ヒトパピローマウイルス(HPV)、ヒト免疫不全ウイルス(HIV)、その他)、検査場所別、地域別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆